BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Roche (RHHBY) Still Hungry for Sequencing Expansion After Failed Attempt to Buy Illumina, Inc. (ILMN)


10/16/2012 8:17:42 AM

Roche Holding AG (ROG) still wants to expand in gene sequencing after this year’s failed effort to buy Illumina Inc. (ILMN) and is looking at potential deals, Chief Executive Officer Severin Schwan said. Illumina fell the most in a year yesterday as investors doubted Roche would renew its interest in buying the world’s biggest maker of DNA sequencing equipment. Illumina declined 6 percent to $48.07 at the close in New York, the biggest drop since Oct. 7, 2011. The San Diego-based company’s shares have gained 58 percent this year. “Sequencing is certainly one of the business areas we are looking to invest in,” Schwan said on a conference call with reporters today after Roche announced a 15 percent increase in third-quarter sales that beat analyst estimates. “We are looking for a variety of options to build this business both internally and externally.” He declined to comment on “market rumors” of a new Illumina bid. Buying Illumina would help Roche, the world’s largest maker of cancer medicines, better tailor drugs to patients. Machines made by Illumina can provide a full transcript of a person’s DNA, information used to diagnose rare disease, identify the risk for a genetic condition, or match cancer treatments to patients’ tumors.

Read at Bloomberg


Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->